Edition:
United States

INC Research Holdings Inc (INCR.OQ)

INCR.OQ on NASDAQ Stock Exchange Global Select Market

41.05USD
15 Dec 2017
Change (% chg)

$0.00 (+0.00%)
Prev Close
$41.05
Open
$41.05
Day's High
$41.28
Day's Low
$40.10
Volume
1,177,138
Avg. Vol
284,351
52-wk High
$61.05
52-wk Low
$33.65

Summary

Name Age Since Current Position

Michael Bell

62 2017 Executive Chairman of the Board

Alistair Macdonald

46 2016 Chief Executive Officer, Director

Gregory Rush

49 2013 Chief Financial Officer, Executive Vice President

Christopher Gaenzle

50 2013 Chief Administrative Officer, General Counsel, Secretary

Todd Abbrecht

2017 Director

Tom Allen

2017 Director

Joshua Nelson

2017 Director

Robert Breckon

59 2010 Independent Director

David Burgstahler

48 2010 Independent Director

Linda Harty

57 2017 Independent Director

Richard Kender

61 2014 Independent Director

William Klitgaard

64 2017 Independent Director

Kenneth Meyers

55 2016 Independent Director

Matthew Monaghan

49 2016 Independent Director

Eric Paques

62 2017 Independent Director

Ronnie Speight

2016 Vice President, Investor Relations

Biographies

Name Description

Michael Bell

Mr. Michael A. Bell serves as Executive Chairman of the Board of the Company. He was Executive Chairman of the Board, President - Commercial Division of the company. served as Chairman and Chief Executive Officer of inVentiv Group Holdings, Inc. from September 2014 until the completion of the Merger. Mr. Bell served as Chief Operating Officer of inVentiv Group Holdings, Inc. from May 2014 until his appointment as Chairman and Chief Executive Officer. From 1998 until he joined inVentiv Group Holdings, Inc., Mr. Bell was a Managing Partner and Founder of Monitor Clipper Partners, a private equity firm where he invested in companies in the professional services, procurement outsourcing and biopharmaceutical services industries. Mr. Bell also served as Senior Executive Vice President of John Hancock Financial Services, Inc., reporting to the Chairman and Chief Executive Officer, from 2001 until the business was sold to Manulife Financial Corporation in 2004. In 1983 Mr. Bell was a founder of Monitor Group, a management consulting firm engaged across the healthcare delivery system, and was a member of the firm’s leadership team until 1998 when he joined Monitor Clipper Partners, LLC.

Alistair Macdonald

Mr. Alistair Macdonald is Chief Executive Officer, Director of the Company. He joined our Company in May 2002 and has served in various senior leadership roles during that time. Prior to his current role, Mr. Macdonald most recently served as President and Chief Operating Officer from January 2015 to September 2016 and Chief Operating Officer from January 2013 to January 2015. He also served as our President, Clinical Development Services from March 2012 to January 2013, Executive Vice President of our Global Oncology Unit from February 2011 to March 2012, Executive Vice President, Strategic Development from October 2009 to February 2011, and Senior Vice President, Biometrics from May 2002 to September 2009. He received his Master of Science in Environmental Diagnostics from Cranfield University.

Gregory Rush

Mr. Gregory S. Rush is Chief Financial Officer, Executive Vice President of the Company. He served as Senior Vice President and Chief Financial Officer of Tekelec, Inc., which was acquired by Oracle Corporation in June 2013, after serving as Interim Chief Financial Officer in March 2010. Mr. Rush joined Tekelec as Vice President and Corporate Controller in May 2005 and served as Vice President, Corporate Controller and Chief Accounting Officer from May 2006 to March 2010. His previous experience also includes roles in various senior financial positions with Siebel Systems, Inc., Quintiles, PricewaterhouseCoopers and Ernst & Young. Mr. Rush received his Bachelor of Science in Business and Master of Accounting degrees from the University of North Carolina at Chapel Hill, graduating with honors, and is a Certified Public Accountant.

Christopher Gaenzle

Mr. Christopher L. Gaenzle is Chief Administrative Officer, General Counsel, Secretary of the Company. He has also served as our Chief Administrative Officer. Prior to joining our Company, Mr. Gaenzle served for five years in various senior legal positions at Pfizer Inc., where he was most recently Assistant General Counsel from 2010 to 2012. Prior to Pfizer, Mr. Gaenzle was a partner at Hunton and Williams LLP, where he was a practicing attorney from 1998 to 2007. Mr. Gaenzle has 20 years of private practice and corporate legal experience, the majority of which is in the pharmaceutical, medical and clinical research industries. Mr. Gaenzle received his Bachelor of Arts from Colgate University and his J.D. from Syracuse University.

Todd Abbrecht

Tom Allen

Joshua Nelson

Robert Breckon

Mr. Robert W. Breckon is Independent Director of the Company. He is a member of the audit committee. Mr. Breckon currently serves as President of Breckon Consultants Inc., which provides consulting services in the healthcare sector, and has been a Senior Advisor to Teachers’ Private Capital, (“Teachers”) since July 2010. He also served as Senior Vice President, Strategy & Corporate Development at MDS Inc., a leading provider of products and services to the global life sciences markets now known as Nordion Inc., from 2005 to 2010, where he led acquisitions and post-acquisition integration assignments in North America, Europe and Asia. Prior to that, he held various senior-level general management positions including VP and General Manager of AutoLab Systems from 1995 to 1999. Mr. Breckon has served on the boards of numerous public and private companies in the United States and Canada, including Heartland Dental, Xenogen Corporation, Evolved Digital Systems Inc., Systems Xcellence Inc., Automed Systems, Inc., InPhact Inc., MDS Proteomics, Hudson Valley Laboratories and Careforce International. Mr. Breckon received his Bachelor of Science in Computer Science and Commerce from the University of Toronto and has completed the Harvard Business School Advanced Management Program.

David Burgstahler

Mr. David F. Burgstahler is Independent Director of the Company. He is the President and Co-Managing Partner of Avista and the Chief Executive Officer of Avista Healthcare Public Acquisition Corp. He was a founding partner of Avista since 2005 and since 2009, has been President of Avista. Prior to forming Avista, he was a partner of DLJ Merchant Banking Partners. He was at DLJ Investment Banking from 1995 to 1997 and at DLJ Merchant Banking Partners from 1997 through 2005. Prior to that, he worked at Andersen Consulting (now known as Accenture) and McDonnell Douglas (now known as Boeing). He holds a Bachelor of Science in Aerospace Engineering from the University of Kansas and a Master of Business Administration from Harvard Business School. He currently serves as a Director of ACP Mountain Holdings, Inc., AngioDynamics Inc., Avista Healthcare Public Acquisition Corp., Lantheus Holdings Inc., Osmotica Holdings Corp. and WideOpenWest, LLC. He previously served as a Director of BioReliance Holdings, Inc., ConvaTec Group plc, Warner Chilcott plc.

Linda Harty

Ms. Linda S. Harty is Independent Director of the Company. She serves as Vice President, Treasurer of Medtronic, a global company specializing in medical technology, services and solutions. Previously, she spent 5 years at Cardinal Health, a global, integrated healthcare services and products company, where she served as Executive Vice President, Treasurer for three years and Executive Vice President, CFO of Healthcare Supply Chain Services Group for two years. Prior to her time at Cardinal, she held financial leadership positions at RTM Restaurant Group, BellSouth, ConAgra and Kimberly-Clark. Ms. Harty earned her undergraduate degrees in finance and economics from the University of Wisconsin – Oshkosh, and furthered her studies in accounting at Georgia State University.

Richard Kender

Mr. Richard N. Kender is Independent Director of the Company. He is a member of the Audit Committee. Mr. Kender is a 35-year veteran in the pharmaceutical industry and spent his entire career at Merck & Co., Inc. Mr. Kender worked across the business in such areas as accounting, finance and business development, holding roles of increasing responsibility. Most recently, he served as Senior Vice President, Business Development and Corporate Licensing from 2000 until his retirement in 2013. Mr. Kender graduated from Villanova University with a Bachelor’s of Science degree in Accounting and earned his MBA from Fairleigh Dickinson University.

William Klitgaard

Mr. William E. Klitgaard is Independent Director of the Company. He is the Chair of the Audit Committee. Mr. Klitgaard currently serves on the Board of Directors at Liaison Technologies, a private company that provides cloud data brokerage services. He also serves on the Enterprise Business Unit Advisory Board for Synchronoss, a global leader in managed mobility solutions for Service Providers and Enterprise, and is a professional consultant in the IT industry. Mr. Klitgaard served as President of Enlighten Health, a division of LabCorp that focuses on innovation and creation of new information-based services utilizing core assets of LabCorp and Covance. Previously, he spent 19 years at Covance, one of the world’s largest contract research organizations, where he served for three years as Corporate Senior Vice President and Chief Information Officer and nearly twelve years as Corporate Senior Vice President and Chief Financial Officer. Prior to his time at Covance, Mr. Klitgaard held finance leadership positions at Kenetech Corporation and Consolidated Freightways, Inc. Mr. Klitgaard completed his undergraduate studies in economics at the University of California at Berkeley, followed by his master’s degree at the Sloan Management School, Massachusetts Institute of Technology.

Kenneth Meyers

Mr. Kenneth F. Meyers is Independent Director of the Company. He is currently, a Senior Vice President and Chief Human Resources Officer at Hill-Rom, a global medical technologies company, he previously held the same role at Hospira, Inc., a manufacturer and distributor of generic injectable pharmaceuticals, biosimilars and medical devices, until its acquisition by Pfizer, Inc. in 2015. Mr. Meyers also has served in senior human resources roles for Mercer/Oliver Wyman, Starbucks Coffee International, The Gymboree Corporation, Walt Disney Imagineering and United Technologies Corporation. Mr. Meyers currently serves on the Board of Directors for Elyssa’s Mission, a community-based non-profit organization dedicated to preventing teen suicide. He also is a member of the Board of Directors and Chair of the Compensation Committee for The Henry P. Kendall Foundation, an organization working to create healthy and sustainable food systems in New England. Mr. Meyers holds a Bachelor’s degree with dual majors in International Business and Human Resource Management from the Wharton School of the University of Pennsylvania and an MBA from the Harvard Business School.

Matthew Monaghan

Mr. Matthew E. Monaghan is Independent Director of the Company. He brings nearly three decades of professional experience in medical device development, operating management for private equity investors, and manufacturing. He is currently Chairman, President and Chief Executive Officer of Invacare Corporation, a medical device manufacturer for the home and long-term healthcare markets. Prior to joining Invacare, he served as Senior Vice President, Hips and Reconstructive Research for Zimmer Holdings, Inc., a global company that designs, develops, manufactures and markets orthopaedic reconstructive, spinal and trauma devices, dental implants, and related surgical products. He also has served in operating management roles for Texas Pacific Group and Cerberus Capital Management. He started his career at General Electric Company, including roles in aerospace and medical systems. Mr. Monaghan is a trustee of Cleveland Clinic Avon Lake Hospital. He holds a Bachelor’s degree in Mechanical Engineering from Cornell University, a Master’s degree in Mechanical Engineering from MIT and an MBA from INSEAD in France.

Eric Paques

Mr. Eric Paul Paques is Independent Director of the Company. He is a member of the Compensation Committee. Mr. Pâques is Chairman of the Supervisory Board of Proteros Biostructure GmbH in Munich (Germany). He is also a professor at the faculty for mathematics, informatics, and natural sciences at RWTH-AACHEN University in Germany. Mr. Pâques previously served as the Chief Executive Officer of the Grünenthal Group. Mr. Pâques started his career at Hoechst AG (later HMR and Aventis) before joining the Grünenthal Group, a research-based family owned pharmaceutical company, in 1994. During his career, he has held leadership positions in various areas of the organization, including Research & Development, M&A, and Licensing among others. Mr. Pâques serves on the Board of Directors of the Grünenthal Group. Mr. Pâques completed his undergraduate studies in chemistry, followed by his doctoral thesis at the Max Planck Institute of Biochemistry in Munich, Germany and the Université Catholique de Louvain in Belgium.

Ronnie Speight